6GDQ
Fragment-based discovery of a highly potent, orally bioavailable inhibitor which modulates the phosphorylation and catalytic activity of ERK1/2
Experimental procedure
Experimental method | SINGLE WAVELENGTH |
Source type | ROTATING ANODE |
Source details | RIGAKU FR-X |
Temperature [K] | 100 |
Detector technology | CCD |
Collection date | 2014-01-09 |
Detector | RIGAKU SATURN 944+ |
Wavelength(s) | 1.54178 |
Spacegroup name | P 1 21 1 |
Unit cell lengths | 48.814, 70.824, 60.334 |
Unit cell angles | 90.00, 109.59, 90.00 |
Refinement procedure
Resolution | 28.420 - 1.860 |
R-factor | 0.183 |
Rwork | 0.180 |
R-free | 0.22600 |
Structure solution method | FOURIER SYNTHESIS |
RMSD bond length | 0.013 |
RMSD bond angle | 1.080 |
Data reduction software | XDS |
Data scaling software | Aimless |
Phasing software | BUSTER |
Refinement software | BUSTER (2.11.7) |
Data quality characteristics
Overall | Outer shell | |
Low resolution limit [Å] | 44.330 | 1.910 |
High resolution limit [Å] | 1.860 | 1.860 |
Rmerge | 0.043 | 0.391 |
Number of reflections | 32676 | 1438 |
<I/σ(I)> | 17 | 2.2 |
Completeness [%] | 94.8 | 64.9 |
Redundancy | 3.2 |
Crystallization Conditions
crystal ID | method | pH | temperature | details |
1 | VAPOR DIFFUSION, SITTING DROP | 7.2 | 293 | 0.2M (NH4)2SO4, 33.0%w/v MPEG 2000, 0.1M HEPES/NaOHpH=7.2, 0.02M Mercaptoethanol |